Bictegravir/emtricitabine/tenofovir alafenamide in older individuals with <scp>HIV</scp> : Results of a 96‐week, phase 3b, open‐label, switch trial in virologically suppressed people ≥65 years of age-Reference-Cited by-同舟云学术

Bictegravir/emtricitabine/tenofovir alafenamide in older individuals with HIV : Results of a 96‐week, phase 3b, open‐label, switch trial in virologically suppressed people ≥65 years of age

Published:2022-05-08 Issue:1 Volume:24 Page:27-36
ISSN:1464-2662
Container-title:HIV Medicine
language:en
Short-container-title:HIV Medicine

Author:

Maggiolo Franco¹,Rizzardini Giuliano²³,Molina Jean‐Michel⁴,Pulido Federico⁵,De Wit Stephane⁶,Vandekerckhove Linos⁷,Berenguer Juan⁸,D'Antoni Michelle L.⁹,Blair Christiana⁹,Chuck Susan K.⁹,Piontkowsky David⁹,Martin Hal⁹,Haubrich Richard⁹,McNicholl Ian R.⁹,Gallant Joel⁹^ORCID

Affiliation:

1. Division of Infectious Diseases ASST Papa Giovanni XXIII Bergamo Italy

2. Division of Infectious Diseases Luigi Sacco Hospital, ASST Fatebenefratelli Sacco Milan Italy

3. School of Clinical Medicine, Faculty of Health Science University of the Witwatersrand Johannesburg South Africa

4. Department of Infectious Diseases, Saint Louis Hospital University Paris Diderot Paris France

5. Unidad VIH Hospital Universitario 12 de Octubre, imas12, UCM Madrid Spain

6. St Pierre University Hospital Université Libre de Bruxelles Brussels Belgium

7. University Hospital Ghent Ghent Belgium

8. Infectious Diseases Hospital General Universitario Gregorio Marañón (IiSGM) Madrid Spain

9. Gilead Sciences Foster City California USA

Funder

Gilead Sciences

Publisher

Wiley

Subject

Pharmacology (medical),Infectious Diseases,Health Policy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hiv.13319

Reference35 articles.

1. Centers for Disease Control and Prevention.HIV and older Americans [Internet].2020. Accessed November 22 2021.https://www.cdc.gov/hiv/group/age/olderamericans/index.html

2. KasaieP StewartC HumesE Gerace L Gebo K Boyd C et al.Multimorbidity in people with HIV using ART in the US: projections to 2030. Presented at: Conference on Retroviruses and Opportunistic Infections (CROI); March 6–10 2021; Virtual. Oral 102.https://www.croiconference.org/abstract/multimorbidity-in-people-with-hiv-using-art-in-the-us-projections-to-2030/

3. Life expectancy in HIV-positive persons in Switzerland

4. Aging and the evolution of comorbidities among HIV-positive individuals in a European cohort

5. Non-HIV Comorbid Conditions and Polypharmacy Among People Living with HIV Age 65 or Older Compared with HIV-Negative Individuals Age 65 or Older in the United States: A Retrospective Claims-Based Analysis

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Relationship between adherence to bictegravir/emtricitabine/tenofovir alafenamide fumarate and clinical outcomes in people with HIV in Japan: a claims database analysis;Scientific Reports;2024-07-22

2. B/F/TAF forgiveness to non-adherence;Sexually Transmitted Infections;2024-07-04

3. Aging on antiretrovirals: reviewing the need for pharmacologic data in elderly people with HIV;AIDS;2024-07-02

4. Twelve-month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in treatment-naïve and treatment-experienced people with HIV: Findings from the Asia cohort of the BICSTaR study;Journal of Microbiology, Immunology and Infection;2024-07

5. Renal safety of tenofovir alafenamide-based antiretroviral therapy in people with HIV: A mini-review;BioScience Trends;2024-04-30